93 results on '"Flamand, V."'
Search Results
2. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR
- Author
-
Reix, B., Bernhard, J.-C., Patard, J.-J., Bigot, P., Villers, A., Suer, E., Vuong, N.S., Verhoest, G., Alimi, Q., Beauval, J.-B., Benoit, T., Nouhaud, F.-X., Lenormand, C., Hamidi, N., Cai, J., Eto, M., Larre, S., El Bakhri, A., Ploussard, G., Hung, A., Koutlidis, N., Schneider, A., Carrouget, J., Droupy, S., Marchal, S., Doerfler, A., Seddik, S., Matsugasumi, T., Orsoni, X., Descazeaud, A., Pfister, C., Bensalah, K., Soulie, M., Gill, I., and Flamand, V.
- Published
- 2018
- Full Text
- View/download PDF
3. Prostatectomie totale de rattrapage après échec de traitement local pour cancer de prostate : morbidité, résultats oncologiques et fonctionnels
- Author
-
Vidmar, R., Marcq, G., Flamand, V., Fantoni, J.-C., Hénon, F., Villers, A., and Ouzzane, A.
- Published
- 2017
- Full Text
- View/download PDF
4. Ureterovesical reimplantation for ureteral deep infiltrating endometriosis: A retrospective study
- Author
-
Chudzinski, A., Collinet, P., Flamand, V., and Rubod, C.
- Published
- 2017
- Full Text
- View/download PDF
5. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project
- Author
-
Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, Wolter, Pascal, Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T.K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P.J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., and Filleron, T.
- Published
- 2015
- Full Text
- View/download PDF
6. Survie sans récidive biologique à long terme après prostatectomie totale pour cancer : analyse comparative selon la voie d’abord et le stade clinico-pathologique
- Author
-
Rizk, J., Ouzzane, A., Flamand, V., Fantoni, J.-C., Puech, P., Leroy, X., and Villers, A.
- Published
- 2015
- Full Text
- View/download PDF
7. Psychometric properties of the psychosocial impact of assistive devices scale (PIADS): A systematic review.
- Author
-
Atigossou, O. L. G., Honado, A. S., Routhier, F., and Flamand, V. H.
- Abstract
The Psychosocial Impact of Assistive Devices Scale (PIADS) is commonly used to assess the psychosocial effects of an assistive device. Given its growing use, an appraisal of the evidence regarding its psychometric properties is required. We conduct a systematic review using validated critical appraisal scales to analyze both the quality and content of the evidence on the psychometric properties of the PIADS. PubMed/Medline, Embase, and CINAHL were systematically searched for identification of studies. Two independent reviewers appraised the retrieved studies using MacDermid and COSMIN-RoB checklists, and extracted data regarding the psychometric measurements reported. MacDermid scores showed that 8 out of 11 studies were, at least, of good methodological quality. COSMIN-RoB scores ranged from inadequate to very good. Except criterion and construct validity, which have presented a moderate level of evidence, the other psychometric properties assessed have demonstrated a high level of evidence. Cross‐cultural validity, measurement error, and responsiveness have not been studied. Few studies have yet evaluated the psychometric properties of the PIADS. However, the quality of the evidence that they provide is mostly adequate. Therefore, this review supports the use of the PIADS, which has overall good psychometric properties. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Mechanical Design Improvement of a Passive Device to Assist Eating in People Living with Movement Disorders
- Author
-
Dub��, Micha��l, Lalibert��, Thierry, Flamand, V��ronique, Routhier, Fran��ois, and Campeau-Lecours, Alexandre
- Subjects
FOS: Computer and information sciences ,Computer Science - Robotics ,Robotics (cs.RO) - Abstract
Many people living with neurological disorders, such as cerebral palsy, stroke, muscular dystrophy or dystonia experience upper limb impairments (muscle spasticity, loss of selective motor control, muscle weakness or tremors) and have difficulty to eat independently. The general goal of this project is to develop a new device to assist with eating, aimed at stabilizing the movement of people who have movement disorders. A first iteration of the device was validated with children living with cerebral palsy and showed promising results. This validation however pointed out important drawbacks. This paper presents an iteration of the design which includes a new mechanism reducing the required arm elevation, improving safety through a compliant utensil attachment, and improving damping and other static balancing factors.
- Published
- 2020
9. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR
- Author
-
Reix, B., Bernhard, J.-C., Patard, J.-J., Bigot, P., Villers, A., Suer, E., Vuong, N. S., Verhoest, G., Alimi, Q., Beauval, J.-B., Benoit, T., Nouhaud, F.-X., Lenormand, C., Hamidi, N., Cai, J., Eto, M., Larre, S., El Bakhri, A., Ploussard, G., Hung, A., Koutlidis, N., Schneider, A., Carrouget, J., Droupy, S., Marchal, S., Doerfler, A., Seddik, S., Matsugasumi, T., Orsoni, X., Descazeaud, A., Pfister, C., Bensalah, K., Soulie, M., Gill, I., Flamand, V., CCAFU, Kidney Cancer, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre d'Études Biologiques de Chizé - UMR 7372 (CEBC), Université de La Rochelle (ULR)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Terres Inovia, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Service d'Urologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Chirurgie urologique et andrologie [CHU Limoges], CHU Limoges, CHU Toulouse [Toulouse], Université Lille Nord de France (COMUE), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de la Recherche Agronomique (INRA)-Université de La Rochelle (ULR)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA)-Université de La Rochelle (ULR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de la Recherche Agronomique (INRA)-La Rochelle Université (ULR)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,medicine.medical_specialty ,Biomedical Research ,Urology ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,International Cooperation ,030232 urology & nephrology ,Outcomes ,Nephrectomy ,Article ,03 medical and health sciences ,Sparing surgery ,Résultats oncologiques ,0302 clinical medicine ,Renal cell carcinoma ,medicine ,Carcinoma ,Partial nephrectomy ,Humans ,Stage (cooking) ,Survival rate ,Néphrectomie partielle ,Carcinoma, Renal Cell ,Aged ,Neoplasm Staging ,Retrospective Studies ,Cancer du rein ,business.industry ,Renal Cell ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,3. Good health ,Survival Rate ,Renal cancer ,Treatment Outcome ,Survie globale ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,Female ,France ,business ,Kidney cancer - Abstract
Summary Background Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. Method A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR). We considered all patients aged ≥ 18 years who underwent surgical treatment for localized renal cell carcinoma (RCC) stage cT2a (7.1–10 cm) between 2000 and 2014. Cox and Fine-Gray models were performed to analyze overall survival (OS), cancer specific survival (CSS) and cancer-free survival (CFS). Comparison between PN and RN was realized after an adjustment by propensity score considering predefined confounding factors: age, sex, tumor size, pT stage of the TNM classification, histological type, ISUP grade, ASA score. Results A total of 267 patients were included. OS at 3 and 5 years was 93.6% and 78.7% after PN and 88.0% and 76.2% after RN, respectively. CSS at 3 and 5 years was 95.4% and 80.2% after PN and 91.0% and 85.0% after RN. No significant difference between groups was found after propensity score adjustment for OS (HR 0.87, 95% CI: 0.37–2.05, P = 0.75), CSS (HR 0.52, 95% CI: 0.18–1.54, P = 0.24) and CFS (HR 1.02, 95% CI: 0.50–2.09, P = 0.96). Conclusion PN seems equivalent to RN for OS, CSS and CFS in cT2a stage kidney tumors. The risk of recurrence is probably more related to prognostic factors than the surgical technique. The decision to perform a PN should depend on technical feasibility rather than tumor size, both to imperative and elective situation. Level of evidence 4.
- Published
- 2017
- Full Text
- View/download PDF
10. Contrôle de la lésion d’ischémie-reperfusion rénale par l’hème oxygenase-1 d’origine myéloïde
- Author
-
Rossi, M., primary, Thierry, A., additional, Delbauve, S., additional, Preyat, N., additional, Soares, M., additional, Leo, O., additional, Roumeguère, T., additional, Flamand, V., additional, Le Moine, A., additional, and Hougardy, J., additional
- Published
- 2018
- Full Text
- View/download PDF
11. Ropan : observatoire national sur la néphrectomie partielle robotisée
- Author
-
Michiels, C., primary, Bernhard, J.C., additional, Beauval, J.B., additional, Doumerc, N., additional, Roupret, M., additional, Vaessen, C., additional, Dariane, C., additional, Flamand, V., additional, Long, J.-A., additional, Paparel, P., additional, Baumert, H., additional, Bruyere, F., additional, Lang, H., additional, Salomon, L., additional, Guilloneau, B., additional, Descazeaud, A., additional, Lebret, T., additional, Arnaud, M., additional, Patard, J., additional, and Bensalah, K., additional
- Published
- 2018
- Full Text
- View/download PDF
12. Ex vivo repair and autotransplantation for complex renal artery aneurysms
- Author
-
Bouye, S., primary, Rizk, J., additional, Azzaoui, R., additional, and Flamand, V., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Résultats anatomopathologiques après prostatectomie totale pour cancer chez des patients éligibles à une surveillance active : apport de l’IRM multiparamétrique dans la décision de traitement
- Author
-
Martin-malburet, A., primary, Marcq, G., additional, Puech, P., additional, Guiffart, P., additional, Fantoni, J., additional, Flamand, V., additional, Villers, A., additional, and Ouzzane, A., additional
- Published
- 2016
- Full Text
- View/download PDF
14. Auto-transplantation rénale pour cure ex-vivo d’anévrisme complexe de l’artère rénale
- Author
-
Bouyé, S., primary, Azzaoui, R., additional, Henon, F., additional, Ouzzane, A., additional, Villers, A., additional, and Flamand, V., additional
- Published
- 2016
- Full Text
- View/download PDF
15. Partial prostatectomy for anterior cancer: Short-term oncological and functional outcomes
- Author
-
Flamand, V., primary, Gill, I., additional, Desai, M., additional, Philippe, P., additional, Crouzet, S., additional, Ouzzane, A., additional, Haber, G-P., additional, Leroy, X., additional, and Villers, A., additional
- Published
- 2016
- Full Text
- View/download PDF
16. 603 Myeloid heme oxygenase-1 controls renal ischemia reperfusion injury
- Author
-
Rossi, M., primary, Thierry, A., additional, Preyat, N., additional, Delbauve, S., additional, Leo, O., additional, Roumeguère, T., additional, Flamand, V., additional, Le Moine, A., additional, and Hougardy, J-M., additional
- Published
- 2016
- Full Text
- View/download PDF
17. Comparaison de la néphrectomie partielle à la néphrectomie élargie pour les cancers à cellules rénales cT2a : survie globale et résultats oncologiques
- Author
-
Reix, B., primary, Flamand, V., additional, Bernhard, J., additional, Bigot, P., additional, and Villers, A., additional
- Published
- 2015
- Full Text
- View/download PDF
18. Cancer du rein cliniquement localisé : quels sont les facteurs prédictifs du risque d’upstaging pathologique pT3a par invasion de la graisse ?
- Author
-
Bernhard, J., primary, Patard, J., additional, Bigot, P., additional, Suer, E., additional, Vuong, N., additional, Verhoest, G., additional, Alimi, Q., additional, Flamand, V., additional, Reix, B., additional, Beauval, J., additional, Benoit, T., additional, Nouhaud, F., additional, Lenormand, C., additional, Hamidi, N., additional, Eto, M., additional, Larre, S., additional, El bakri, A., additional, Baco, E., additional, Ploussard, G., additional, Koutlidis, N., additional, Schneider, A., additional, Roupret, M., additional, Leon, P., additional, Carrouget, J., additional, Droupy, S., additional, and Marchal, S., additional
- Published
- 2015
- Full Text
- View/download PDF
19. V34 Robotic single port radical prostatectomy: First clinical investigation using a novel robotic system
- Author
-
Flamand, V., primary, Kaouk, J., additional, Autorino, R., additional, Crouzet, S., additional, Ouzzane, A., additional, Haber, G-P., additional, and Villers, A., additional
- Published
- 2015
- Full Text
- View/download PDF
20. V28 Novel robotic platform for single port partial nephrectomy
- Author
-
Ramirez, D., primary, Flamand, V., additional, Villers, A., additional, and Kaouk, J.H., additional
- Published
- 2015
- Full Text
- View/download PDF
21. 915 Is laparoscopic partial nephrectomy a safe treatment option for unexpected pT3a renal cell carcinoma?
- Author
-
Bernhard, J-C., primary, Patard, J-J., additional, Bigot, P., additional, Suer, E., additional, Vuong, N.S., additional, Verhoest, G., additional, Alimi, Q., additional, Flamand, V., additional, Reix, B., additional, Beauval, J-B., additional, Benoit, T., additional, Nouhaud, F-X, additional, Lenormand, C., additional, Hamidi, N., additional, Hung, A., additional, Cai, J., additional, Eto, M., additional, Larre, S., additional, El Bakri, A., additional, Baco, E., additional, Ploussard, G., additional, Koutlidis, N., additional, Schneider, A., additional, Roupret, M., additional, Leon, P., additional, Carrouget, J., additional, Droupy, S., additional, Marchal, S., additional, Doerfler, A., additional, Sofiane, S., additional, Matsugasumi, T., additional, Orsoni, X., additional, Descazeaud, A., additional, Pfister, C., additional, Bensalah, K., additional, Méjean, A., additional, Soulie, M., additional, and Gill, I., additional
- Published
- 2015
- Full Text
- View/download PDF
22. 727 From clinically localized to pT3a renal cell carcinoma: What are the predictive factors of unexpected pathologic upstaging?
- Author
-
Bernhard, J-C., primary, Patard, J-J., additional, Bigot, P., additional, Suer, E., additional, Vuong, N.S., additional, Verhoest, G., additional, Alimi, Q., additional, Flamand, V., additional, Reix, B., additional, Beauval, J-B., additional, Benoit, T., additional, Nouhaud, F-X., additional, Lenormand, C., additional, Hamidi, N., additional, Hung, A., additional, Cai, J., additional, Eto, M., additional, Larre, S., additional, El Bakri, A., additional, Baco, E., additional, Ploussard, G., additional, Koutlidis, N., additional, Schneider, A., additional, Roupret, M., additional, Leon, P., additional, Carrouget, J., additional, Droupy, S., additional, Marchal, S., additional, Doerfler, A., additional, Seddik, S., additional, Matsugasumi, T., additional, Orsoni, X., additional, Descazeaud, A., additional, Pfister, C., additional, Bensalah, K., additional, Méjean, A., additional, Soulie, M., additional, and Gill, I., additional
- Published
- 2015
- Full Text
- View/download PDF
23. V11 - Ex vivo repair and autotransplantation for complex renal artery aneurysms
- Author
-
Bouye, S., Rizk, J., Azzaoui, R., and Flamand, V.
- Published
- 2017
- Full Text
- View/download PDF
24. VE32 - Partial prostatectomy for anterior cancer: Short-term oncological and functional outcomes
- Author
-
Flamand, V., Gill, I., Desai, M., Philippe, P., Crouzet, S., Ouzzane, A., Haber, G-P., Leroy, X., and Villers, A.
- Published
- 2016
- Full Text
- View/download PDF
25. Cancer du rein cliniquement localisé : quels sont les facteurs prédictifs du risque d’upstagingpathologique pT3a par invasion de la graisse ?
- Author
-
Bernhard, J., Patard, J., Bigot, P., Suer, E., Vuong, N., Verhoest, G., Alimi, Q., Flamand, V., Reix, B., Beauval, J., Benoit, T., Nouhaud, F., Lenormand, C., Hamidi, N., Eto, M., Larre, S., El bakri, A., Baco, E., Ploussard, G., Koutlidis, N., Schneider, A., Roupret, M., Leon, P., Carrouget, J., Droupy, S., and Marchal, S.
- Abstract
Le cancer du rein (CCR) de stade pT3a s’accompagne d’un moins bon pronostic que les stades localisés. Néanmoins, au moment de la décision thérapeutique, la majorité des cas sont initialement considérés comme localisés. L’objectif de notre étude était de définir des facteurs de risque d’upstagingpathologique T3a.
- Published
- 2015
- Full Text
- View/download PDF
26. High salt diet alleviates disease severity in native experimental autoimmune uveitis.
- Author
-
Derluyn N, Foucart V, Verce M, Abdo R, Vaudoisey L, Lipski D, Flamand V, Everard A, Bruyns C, and Willermain F
- Abstract
Background: Recent studies reported a link between high salt diet (HSD) and clinical exacerbation in mouse models of autoimmune diseases, mainly through the induction of pathogenic Th17 cells and/or HSD-induced dysbiosis. However, the topic remains controversial and not fully understood., Purpose: In this study, we investigated the effects of HSD on the development of experimental autoimmune uveitis (EAU) in C57BL/6J mice., Methods and Results: Unexpectedly, our data showed a significant attenuating effect of HSD on disease severity of native EAU, induced by direct immunization with IRBP peptide. That said, HSD had no effect on EAU disease severity induced by adoptive transfer of semi-purified auto-reactive IRBP-specific T lymphocytes. Accordingly, HSD did not affect IRBP-specific systemic afferent immune response as attested by no HSD-linked changes in T lymphocytes proliferation, cytokine production and Treg proportion. Gut microbiota analysis from cecal samples in naïve and EAU mice demonstrated that HSD affected differentially α-diversity between groups, whereas β-diversity was significantly modified in all groups. Unknown Tannerellaceae was the only taxon associated to HSD exposure in all treatment groups. Interestingly, a significantly higher abundance of unknown Gastranaerophilales , with potential anti-inflammatory properties, appeared in HSD-fed native EAU mice, only., Discussion: In conclusion, our study suggests a possible impact of HSD on gut microbiota composition and consequently on development and clinical severity of EAU. Further studies are required to investigate the potential beneficial role of Gastranaerophilales in EAU., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Derluyn, Foucart, Verce, Abdo, Vaudoisey, Lipski, Flamand, Everard, Bruyns and Willermain.)
- Published
- 2024
- Full Text
- View/download PDF
27. The REHAB-LAB model for individualized assistive device co-creation and production.
- Author
-
Lamontagne ME, Pellichero A, Tostain V, Routhier F, Flamand V, Campeau-Lecours A, Gherardini F, Thébaud M, Coignard P, and Allègre W
- Subjects
- Humans, Activities of Daily Living, Self-Help Devices, Persons with Disabilities rehabilitation
- Abstract
Assistive devices are designed to enhance individuals with disabilities' functional abilities. The rise of 3D printing technology enabled the production of individualized assistive devices (IADs). A REHAB-LAB is intended for IAD provision involving technical referents and occupational therapists. This study aimed to develop the REHAB-LAB logic model; to explore its fidelity and desirability; and to explore the characteristics of arising initiatives of IAD production. The REHAB-LAB logic model development involved stakeholders throughout the research process. A pragmatic multimethod approach followed two phases 1) logic model development and 2) exploration of its fidelity and desirability. The REHAB-LAB logic model presented the resources (equipment, space, human) required to implement IAD provision in a rehabilitation center, and the expected deliverables (activities and outputs). The REHAB-LAB logic model highlights the interdisciplinarity of IAD provision including occupational therapists, doctors, engineers, managers, and technical referents and places the users at the center of the IAD production. Results confirmed the fidelity and desirability of the REHAB-LAB logic model. The REHAB-LAB logic model can be used as a reference for future healthcare organizations wishing to implement an IAD provision. This research highlighted the interest of IAD provision based on the REHAB-LAB model involving users and transdisciplinary practices.
- Published
- 2024
- Full Text
- View/download PDF
28. Macrophage-infectivity potentiator of Trypanosoma cruzi (TcMIP) is a new pro-type 1 immuno-stimulating protein for neonatal human cells and vaccines in mice.
- Author
-
Radwanska M, de Lemos Esteves F, Linsen L, Coltel N, Cencig S, Widart J, Massart AC, Colson S, Di Paolo A, Percier P, Ait Djebbara S, Guillonneau F, Flamand V, De Pauw E, Frère JM, Carlier Y, and Truyens C
- Subjects
- Humans, Mice, Infant, Newborn, Animals, Adjuvants, Immunologic pharmacology, Antigens, Immunoglobulin G, Macrophages, Trypanosoma cruzi, Vaccines
- Abstract
This work identifies the protein "macrophage infectivity potentiator" of Trypanosoma cruzi trypomastigotes, as supporting a new property, namely a pro-type 1 immunostimulatory activity on neonatal cells. In its recombinant form (rTcMIP), this protein triggers the secretion of the chemokines CCL2 and CCL3 by human umbilical cord blood cells from healthy newborns, after 24h in vitro culture. Further stimulation for 72h results in secretion of IFN-γ, provided cultures are supplemented with IL-2 and IL-18. rTcMIP activity is totally abolished by protease treatment and is not associated with its peptidyl-prolyl cis-trans isomerase enzymatic activity. The ability of rTcMIP to act as adjuvant was studied in vivo in neonatal mouse immunization models, using acellular diphtheria-tetanus-pertussis-vaccine (DTPa) or ovalbumin, and compared to the classical alum adjuvant. As compared to the latter, rTcMIP increases the IgG antibody response towards several antigens meanwhile skewing antibody production towards the Th-1 dependent IgG2a isotype. The amplitude of the rTcMIP adjuvant effect varied depending on the antigen and the co-presence of alum. rTcMIP did by contrast not increase the IgE response to OVA combined with alum. The discovery of the rTcMIP immunostimulatory effect on neonatal cells opens new possibilities for potential use as pro-type 1 adjuvant for neonatal vaccines. This, in turn, may facilitate the development of more efficient vaccines that can be given at birth, reducing infection associated morbidity and mortality which are the highest in the first weeks after birth., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Radwanska, de Lemos Esteves, Linsen, Coltel, Cencig, Widart, Massart, Colson, Di Paolo, Percier, Ait Djebbara, Guillonneau, Flamand, De Pauw, Frère, Carlier and Truyens.)
- Published
- 2023
- Full Text
- View/download PDF
29. Maternal Lactobacillus rhamnosus administration impacts neonatal CD4 T-cell activation and prevents murine T helper 2-type allergic airways disease.
- Author
-
Smout J, Valentin C, Delbauve S, Pauwels J, Köhler A, and Flamand V
- Subjects
- Mice, Child, Preschool, Humans, Animals, CD4-Positive T-Lymphocytes, Nuclear Receptor Subfamily 1, Group F, Member 3 metabolism, Th2 Cells, Mice, Inbred C57BL, Lung, Forkhead Transcription Factors metabolism, Lacticaseibacillus rhamnosus, Hypersensitivity prevention & control, Hypersensitivity metabolism, Respiration Disorders
- Abstract
Gut microbiota plays a role in the neonatal immune education and could influence susceptibility to Th2-type immune disorders, such as allergies, the most prevalent chronic diseases in early childhood. We studied the impact of oral Lactobacillus rhamnosus ( L.rhamnosus ) supplementation to pregnant/breastfeeding C57BL/6 mice on the development of allergic airways disease in their offspring. We observed that mice, from L.rhamnosus -treated mothers, inoculated with ovalbumin (OVA)-Aluminium hydroxide (ALUM) at 3 days of life and challenged intranasally 4 weeks later showed decreased Th2-associated cytokines, IgE and IgG1, lung eosinophilia and airway hyper-reactivity compared to OVA-sensitized mice from untreated mothers. In that setting, the L.rhamnosus treatment increased the number and maturation of splenic neonatal type 1 conventional dendritic cells (cDC1) that remained largely dominant over the cDC2 and favored their OVA-specific Th1 differentiation. In response to inhaled house dust mite (HDM) allergen, the maternal L.rhamnosus supplementation increased the number of neonatal pulmonary cDC1 expressing lower amount of costimulatory molecules compared with no supplementation and decreased the number of cDC2 without affecting their costimulatory molecules expression. An HDM-specific Foxp3
+ RORγt+ Treg polarization was monitored in the lung draining lymph nodes. Finally, we confirmed the inhibitory effect of maternal L.rhamnosus treatment on all the measured features of the HDM allergic airways reaction in their offspring. We conclude that maternal L.rhamnosus administration prevents Th2-type allergic airways disease in their neonates by favoring splenic cDC1/Th1 responses against ALUM-adjuvanted OVA or by promoting a pulmonary Foxp3+ RORγt+ Treg activation against inhaled HDM., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Smout, Valentin, Delbauve, Pauwels, Köhler and Flamand.)- Published
- 2023
- Full Text
- View/download PDF
30. From maternal breath to infant's cells: Impact of maternal respiratory infections on infants 'immune responses.
- Author
-
Dauby N and Flamand V
- Abstract
In utero exposure to maternally-derived antigens following chronic infection is associated with modulation of infants 'immune response, differential susceptibility to post-natal infections and immune response toward vaccines. The maternal environment, both internal (microbiota) and external (exposure to environmental microbes) also modulates infant's immune response but also the clinical phenotype after birth. Vertical transmission of ubiquitous respiratory pathogens such as influenza and COVID-19 is uncommon. Evidence suggest that in utero exposure to maternal influenza and SARS-CoV-2 infections may have a significant impact on the developing immune system with activation of both innate and adaptive responses, possibly related to placental inflammation. Here in, we review how maternal respiratory infections, associated with airway, systemic and placental inflammation but also changes in maternal microbiota might impact infant's immune responses after birth. The clinical impact of immune modifications observed following maternal respiratory infections remains unexplored. Given the high frequencies of respiratory infections during pregnancy (COVID-19, influenza but also RSV and HMPV), the impact on global child health could be important., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2022 Dauby and Flamand.)
- Published
- 2022
- Full Text
- View/download PDF
31. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
- Author
-
Celus W, Oliveira AI, Rivis S, Van Acker HH, Landeloos E, Serneels J, Cafarello ST, Van Herck Y, Mastrantonio R, Köhler A, Garg AD, Flamand V, Tamagnone L, Marine JC, Di Matteo M, Costa BM, Bechter O, and Mazzone M
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Humans, Lung Neoplasms immunology, Lung Neoplasms pathology, Lymphocyte Activation, Melanoma, Experimental immunology, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Nerve Tissue Proteins genetics, Programmed Cell Death 1 Receptor immunology, Receptors, Cell Surface genetics, Tumor Microenvironment immunology, Immunotherapy methods, Lung Neoplasms therapy, Melanoma, Experimental therapy, Nerve Tissue Proteins pharmacology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Cytotoxic T cell (CTL) infiltration of the tumor carries the potential to limit cancer progression, but their exclusion by the immunosuppressive tumor microenvironment hampers the efficiency of immunotherapy. Here, we show that expression of the axon guidance molecule Plexin-A4 ( Plxna4 ) in CTLs, especially in effector/memory CD8
+ T cells, is induced upon T-cell activation, sustained in the circulation, but reduced when entering the tumor bed. Therefore, we deleted Plxna4 and observed that Plxna4 -deficient CTLs acquired improved homing capacity to the lymph nodes and to the tumor, as well as increased proliferation, both achieved through enhanced Rac1 activation. Mice with stromal or hematopoietic Plxna4 deletion exhibited enhanced CTL infiltration and impaired tumor growth. In a melanoma model, adoptive transfer of CTLs lacking Plxna4 prolonged survival and improved therapeutic outcome, which was even stronger when combined with anti-programmed cell death protein 1 (PD-1) treatment. PLXNA4 abundance in circulating CTLs was augmented in melanoma patients versus healthy volunteers but decreased after the first cycle of anti-PD-1, alone or in combination with anti-cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), in those patients showing complete or partial response to the treatment. Altogether, our data suggest that Plxna4 acts as a "checkpoint," negatively regulating CTL migration and proliferation through cell-autonomous mechanisms independent of the interaction with host-derived Plxna4 ligands, semaphorins. These findings pave the way toward Plxna4-centric immunotherapies and propose Plxna4 detection in circulating CTLs as a potential way to monitor the response to immune checkpoint blockade in patients with metastatic melanoma., (©2021 The Authors; Published by the American Association for Cancer Research.)- Published
- 2022
- Full Text
- View/download PDF
32. Aconitate decarboxylase 1 participates in the control of pulmonary Brucella infection in mice.
- Author
-
Demars A, Vitali A, Comein A, Carlier E, Azouz A, Goriely S, Smout J, Flamand V, Van Gysel M, Wouters J, Abendroth J, Edwards TE, Machelart A, Hoffmann E, Brodin P, De Bolle X, and Muraille E
- Subjects
- Animals, Isocitrate Lyase metabolism, Mice, Mice, Inbred C57BL, Brucellosis immunology, Carboxy-Lyases immunology, Lung Diseases immunology, Macrophages, Alveolar immunology
- Abstract
Brucellosis is one of the most widespread bacterial zoonoses worldwide. Here, our aim was to identify the effector mechanisms controlling the early stages of intranasal infection with Brucella in C57BL/6 mice. During the first 48 hours of infection, alveolar macrophages (AMs) are the main cells infected in the lungs. Using RNA sequencing, we identified the aconitate decarboxylase 1 gene (Acod1; also known as Immune responsive gene 1), as one of the genes most upregulated in murine AMs in response to B. melitensis infection at 24 hours post-infection. Upregulation of Acod1 was confirmed by RT-qPCR in lungs infected with B. melitensis and B. abortus. We observed that Acod1-/- C57BL/6 mice display a higher bacterial load in their lungs than wild-type (wt) mice following B. melitensis or B. abortus infection, demonstrating that Acod1 participates in the control of pulmonary Brucella infection. The ACOD1 enzyme is mostly produced in mitochondria of macrophages, and converts cis-aconitate, a metabolite in the Krebs cycle, into itaconate. Dimethyl itaconate (DMI), a chemically-modified membrane permeable form of itaconate, has a dose-dependent inhibitory effect on Brucella growth in vitro. Interestingly, structural analysis suggests the binding of itaconate into the binding site of B. abortus isocitrate lyase. DMI does not inhibit multiplication of the isocitrate lyase deletion mutant ΔaceA B. abortus in vitro. Finally, we observed that, unlike the wt strain, the ΔaceA B. abortus strain multiplies similarly in wt and Acod1-/- C57BL/6 mice. These data suggest that bacterial isocitrate lyase might be a target of itaconate in AMs., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
33. Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
- Author
-
Germanova D, Keirsse J, Köhler A, Hastir JF, Demetter P, Delbauve S, Elkrim Y, Verset L, Larbanoix L, Preyat N, Laurent S, Nedospasov S, Donckier V, Van Ginderachter JA, and Flamand V
- Subjects
- Animals, Disease Progression, Kupffer Cells physiology, Male, Mice, Mice, Inbred C57BL, Monocytes physiology, Receptor-Interacting Protein Serine-Threonine Kinases physiology, Colorectal Neoplasms pathology, Heme Oxygenase-1 physiology, Liver blood supply, Liver Neoplasms etiology, Liver Neoplasms secondary, Neoplasm Recurrence, Local etiology, Reperfusion Injury complications, Tumor Necrosis Factor-alpha physiology
- Abstract
The liver ischemia-reperfusion (IR) injury that occurs consequently to hepatic resection performed in patients with metastases can lead to tumor relapse for not fully understood reasons. We assessed the effects of liver IR on tumor growth and the innate immune response in a mouse model of colorectal (CR) liver metastasis. Mice subjected to liver ischemia 2 days after intrasplenic injection of CR carcinoma cells displayed a higher metastatic load in the liver, correlating with Kupffer cells (KC) death through the activation of receptor-interating protein 3 kinase (RIPK3) and caspase-1 and a recruitment of monocytes. Interestingly, the immunoregulatory mediators, tumor necrosis factor-α (TNF-α) and heme oxygenase-1 (HO-1) were strongly upregulated in recruited monocytes and were also expressed in the surviving KC following IR. Using TNF
flox/flox LysMcre/wt mice, we showed that TNF deficiency in macrophages and monocytes favors tumor progression after IR. The antitumor effect of myeloid cell-derived TNF involved direct tumor cell apoptosis and a reduced expression of immunosuppressive molecules such as transforming growth factor-β, interleukin (IL)-10, inducible nitric oxyde synthase (iNOS), IL-33 and HO-1. Conversely, a monocyte/macrophage-specific deficiency in HO-1 (HO-1flox/flox LysMcre/wt ) or the blockade of HO-1 function led to the control of tumor progression post-liver IR. Importantly, host cell RIPK3 deficiency maintains the KC number upon IR, inhibits the IR-induced innate cell recruitment, increases the TNF level, decreases the HO-1 level and suppresses the tumor outgrowth. In conclusion, tumor recurrence in host undergoing liver IR is associated with the death of antitumoral KC and the recruitment of monocytes endowed with immunosuppressive properties. In both of which HO-1 inhibition would reinforce their antitumoral activity., (© 2020 UICC.)- Published
- 2021
- Full Text
- View/download PDF
34. Very early-life exposure to microbiota-induced TNF drives the maturation of neonatal pre-cDC1.
- Author
-
Köhler A, Delbauve S, Smout J, Torres D, and Flamand V
- Subjects
- Cell Differentiation, Cytokines metabolism, Humans, Immune Tolerance, Immunity, Innate, Infant, Newborn, Listeria monocytogenes, Macrophages immunology, Macrophages metabolism, Monocytes immunology, Monocytes metabolism, Phenotype, Signal Transduction, Spleen metabolism, Tumor Necrosis Factor-alpha metabolism, Cytokines immunology, Dendritic Cells immunology, Microbiota immunology, Tumor Necrosis Factor-alpha immunology
- Abstract
Objective: Induction of immune protection against pathogens is particularly crucial during the neonatal period dominated by anti-inflammatory and tolerance immunity. The preclinical study was carried out to determine whether environmental factors such as microbiota may influence early life immunity by impacting the development and the functional maturation of precursors of type 1 conventional dendritic cells (pre-cDC1), endowed with regulatory properties., Design: Pre-cDC1 phenotype and cytokine expression in the spleen of neonates from antibiotic-treated mothers were established. The role of myeloid-derived tumour necrosis factor (TNF) was tested in vitro and in vivo. RNA sequencing analysis on neonatal sorted pre-cDC1 was performed. The early life protective CD8
+ T-cell response against Listeria monocytogenes was monitored., Results: We observed that first exposure to microbiota promotes TNF secretion by monocytes and macrophages shortly after birth. We demonstrated that this myeloid-derived inflammatory cytokine is crucial to induce the maturation of these neonatal regulatory pre-cDC1. Myeloid TNF signalling acts on C1q and β-catenin pathway and modifies the fatty acid metabolism in neonatal pre-cDC1. Furthermore, we showed that during neonatal L. monocytogenes infection, microbiota-associated myeloid TNF promotes the capacity of these pre-cDC1 to induce protective CD8+ T-cell responses, by modulating their ability to secrete interleukin-10 (IL-10) and IL-12p40., Conclusion: Our findings emphasise the role of microbiota-derived TNF to kick-start the differentiation and the functional maturation of the neonatal splenic pre-cDC1 compartment. They bring a better understanding of potential mechanisms underlying some microbiota-linked immune dysfunction in early life., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
35. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.
- Author
-
Spilleboudt C, De Wilde V, Lewalle P, Cabanne L, Leclerc M, Beckerich F, Bories D, Cardoso S, Soares MP, Vokaer B, Hougardy JM, Flamand V, Racapé J, Abramowicz M, Maury S, and Le Moine A
- Subjects
- Adult, Animals, Disease Models, Animal, Female, Genetic Predisposition to Disease, Graft vs Host Disease enzymology, Graft vs Host Disease genetics, Graft vs Host Disease immunology, Heme Oxygenase-1 genetics, Homozygote, Humans, Male, Membrane Proteins genetics, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Microsatellite Repeats, Middle Aged, Myeloid-Derived Suppressor Cells enzymology, Phenotype, Polymorphism, Genetic, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Mice, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Heme Oxygenase-1 metabolism, Membrane Proteins metabolism, Myeloid-Derived Suppressor Cells transplantation
- Abstract
Graft-versus-host disease (GVHD) remains a major clinical drawback of allogeneic hematopoietic stem cell transplantation (HSCT). Here, we investigated how the stress responsive heme catabolizing enzyme heme oxygenase-1 (HO-1, encoded by HMOX1 ) regulates GVHD in response to allogeneic hematopoietic stem cell transplantation in mice and humans. We found that deletion of the Hmox1 allele, specifically in the myeloid compartment of mouse donor bone marrow, promotes the development of aggressive GVHD after allogeneic transplantation. The mechanism driving GVHD in mice transplanted with allogeneic bone marrow lacking HO-1 expression in the myeloid compartment involves enhanced T cell alloreactivity. The clinical relevance of these observations was validated in two independent cohorts of HSCT patients. Individuals transplanted with hematopoietic stem cells from donors carrying a long homozygous (GT)
n repeat polymorphism (L/L) in the HMOX1 promoter, which is associated with lower HO-1 expression, were at higher risk of developing severe acute GVHD as compared to donors carrying a short (GT)n repeat (S/L or S/S) polymorphism associated with higher HO-1 expression. In this study, we showed the unique importance of donor-derived myeloid HO-1 in the prevention of lethal experimental GVHD and we corroborated this observation by demonstrating the association between human HMOX1 (GT)n microsatellite polymorphisms and the incidence of severe acute GVHD in two independent HSCT patient cohorts. Donor-derived myeloid HO-1 constitutes a potential therapeutic target for HSCT patients and large-scale prospective studies in HSCT patients are necessary to validate the HO-1 L/L genotype as an independent risk factor for developing severe acute GVHD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Spilleboudt, De Wilde, Lewalle, Cabanne, Leclerc, Beckerich, Bories, Cardoso, Soares, Vokaer, Hougardy, Flamand, Racapé, Abramowicz, Maury and Le Moine.)- Published
- 2021
- Full Text
- View/download PDF
36. Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy.
- Author
-
Hastir JF, Delbauve S, Larbanoix L, Germanova D, Goyvaerts C, Allard J, Laurent S, Breckpot K, Beschin A, Guilliams M, and Flamand V
- Abstract
Partial hepatectomy (PH) is the main treatment for early-stage hepatocellular carcinoma (HCC). Yet, a significant number of patients undergo recursion of the disease that could be linked to the fate of innate immune cells during the liver regeneration process. In this study, using a murine model, we investigated the impact of PH on HCC development by bioluminescence imaging and flow cytometry. While non-resected mice were able to control and reject orthotopic implanted Hepa1-6 hepatocarcinoma cells, resected liver underwent an increased tumoral proliferation. This phenomenon was associated with a PH-induced reduction in the number of liver-resident macrophages, i.e., Kupffer cells (KC). Using a conditional ablation model, KC were proved to participate in Hepa1-6 rejection. We demonstrated that in the absence of Hepa1-6, PH-induced KC number reduction was dependent on tumor necrosis factor-alpha (TNF-α), receptor-interacting protein kinase (RIPK) 3, and caspase-8 activation, whereas interleukin (IL)-6 acted as a KC pro-survival signal. In mice with previous Hepa1-6 encounter, the KC reduction switched toward a TNF-α-RIPK3-caspase-1 activation. Moreover, KC disappearance associated with caspase-1 activity induced the recruitment of monocyte-derived cells that are beneficial for tumor growth, while caspase-8-dependent reduction did not. In conclusion, our study highlights the importance of the TNF-α-dependent death pathway induced in liver macrophages following partial hepatectomy in regulating the antitumoral immune responses., (Copyright © 2020 Hastir, Delbauve, Larbanoix, Germanova, Goyvaerts, Allard, Laurent, Breckpot, Beschin, Guilliams and Flamand.)
- Published
- 2020
- Full Text
- View/download PDF
37. HO-1 mitigates acute kidney injury and subsequent kidney-lung cross-talk.
- Author
-
Rossi M, Delbauve S, Roumeguère T, Wespes E, Leo O, Flamand V, Le Moine A, and Hougardy JM
- Subjects
- Acute Kidney Injury, Animals, Disease Models, Animal, Heme Oxygenase-1 pharmacology, Humans, Kidney pathology, Lung pathology, Male, Mice, Heme Oxygenase-1 therapeutic use, Inflammation etiology, Kidney drug effects, Lung drug effects
- Abstract
Ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI), which contributes to the development of chronic kidney disease (CKD). IRI-induced AKI releases proinflammatory cytokines (e.g. IL-1β, TNF-α, IL-6) that induce a systemic inflammatory response, resulting in proinflammatory cells recruitment and remote organ damage. AKI is associated with poor outcomes, particularly when extrarenal complications or distant organ injuries occur. Acute lung injury (ALI) is a major remote organ dysfunction associated with AKI. Hence, kidney-lung cross-talk remains a clinical challenge, especially in critically ill population. The stress-responsive enzyme, heme oxygenase-1 (HO-1) is largely known to protect against renal IRI and may be preventively induced using hemin prior to renal insult. However, the use of hemin-induced HO-1 to prevent AKI-induced ALI remains poorly investigated. Mice received an intraperitoneal injection of hemin or sterile saline 1 day prior to surgery. Twenty-four hours later, mice underwent bilateral renal IRI for 26 min or sham surgery. After 4 or 24 h of reperfusion, mice were sacrificed. Hemin-induced HO-1 improved renal outcomes after IRI (i.e. fewer renal damage, renal inflammation, and oxidative stress). This protective effect was associated with a dampened systemic inflammation (i.e. IL-6 and KC). Subsequently, mitigated lung inflammation was found in hemin-treated mice (i.e. neutrophils influx and lung KC). The present study demonstrates that hemin-induced HO-1 controls the magnitude of renal IRI and the subsequent AKI-induced ALI. Therefore, targeting HO-1 represents a promising approach to prevent the impact of renal IRI on distant organs, such as lung.
- Published
- 2019
- Full Text
- View/download PDF
38. Dual effect of hemin on renal ischemia-reperfusion injury.
- Author
-
Rossi M, Delbauve S, Wespes E, Roumeguère T, Leo O, Flamand V, Le Moine A, and Hougardy JM
- Subjects
- Acute Kidney Injury enzymology, Acute Kidney Injury genetics, Acute Kidney Injury pathology, Animals, Dose-Response Relationship, Drug, Gene Expression Regulation, Heme Oxygenase-1 metabolism, Kidney drug effects, Kidney enzymology, Kidney pathology, Male, Membrane Proteins metabolism, Mice, Mice, Inbred C57BL, Oxidative Stress drug effects, Reperfusion Injury enzymology, Reperfusion Injury genetics, Reperfusion Injury pathology, Time Factors, Acute Kidney Injury prevention & control, Heme Oxygenase-1 genetics, Hemin pharmacology, Ischemic Preconditioning methods, Membrane Proteins genetics, Reperfusion Injury prevention & control
- Abstract
Acute kidney injury (AKI) is a major public health concern, which is contributing to serious hospital complications, chronic kidney disease (CKD) and even death. Renal ischemia-reperfusion injury (IRI) remains a leading cause of AKI. The stress-responsive enzyme, heme oxygenase-1 (HO-1) mediates protection against renal IRI and may be preventively induced using hemin prior to renal insult. This HO-1 induction pathway called hemin preconditioning is largely known to be effective. Therefore, HO-1 might be an interesting therapeutic target in case of predictable AKI (e.g. partial nephrectomy or renal transplantation). However, the use of hemin to mitigate established AKI remains poorly characterized. Mice underwent bilateral renal IRI for 26 min or sham surgery. After surgical procedure, animals were injected either with hemin (5 mg/kg) or vehicle. Twenty-four hours later, mice were sacrificed. Despite strong HO-1 induction, hemin-treated mice exhibited significant renal damage and oxidative stress as compared to vehicle-treated mice. Interestingly, higher dose of hemin is associated with more severe IRI-induced AKI in a dose-dependent relation. To determine whether hemin preconditioning remains efficient to dampen postoperative hemin-amplified IRI-induced AKI, we pretreated mice either with hemin (5 mg/kg) or vehicle 24 h prior to surgical procedure. Then, all mice (hemin- and vehicle-pretreated) received postoperative injection of hemin (5 mg/kg) to amplify IRI-induced AKI. In comparison to vehicle, prior administration of hemin to renal IRI mitigated hemin-amplified IRI-induced AKI as attested by fewer renal damage, inflammation and oxidative stress. In conclusion, hemin may have a dual effect on renal IRI, protective or deleterious, depending on the timing of its administration., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
39. Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes.
- Author
-
Villers A, Puech P, Flamand V, Haber GP, Desai MM, Crouzet S, Leroy X, Chopra S, Lemaitre L, Ouzzane A, and Gill IS
- Subjects
- Aged, Biopsy, Feasibility Studies, Humans, Kallikreins blood, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Grading, Postoperative Complications etiology, Prospective Studies, Prostate-Specific Antigen blood, Prostatectomy adverse effects, Prostatic Neoplasms blood, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology, Risk Assessment, Surveys and Questionnaires, Time Factors, Treatment Outcome, Prostatectomy methods, Prostatic Neoplasms surgery, Robotic Surgical Procedures adverse effects
- Abstract
Background: Focal ablative therapy may be a suboptimal option for anterior prostate cancers (APCs) reaching the prostate apex due to concerns for thermal injury to the external sphincter., Objective: To explore the technical feasibility of anterior partial prostatectomy (APP) for isolated APCs detected by magnetic resonance imaging (MRI), and to report short-term oncologic and functional outcomes., Design, Setting, and Participants: Following institutional review board approval, over an 8-yr period (2008-2015) 17 consenting patients were enrolled in a prospective single-arm single-center Innovation, Development, Exploration, Assessment, Long-term (IDEAL) phase 2a study. Inclusion criteria comprised preurethral, low- to intermediate-risk APC diagnosed by MRI, and targeted biopsies. Robotic template APP was performed; posterolateral aspect of the submontanal urethra, peripheral zone, and periprostatic tissues were preserved intact. Median follow-up was 30 mo (interquartile range [IQR]: 25-70)., Outcome Measurements and Statistical Analysis: We noted the incidence of perioperative complications and examined reports of pathology, prostate-specific antigen (PSA), imaging, biopsies, and questionnaires., Results and Limitations: Preoperatively, median PSA was 9.8 ng/ml, Gleason score was 6-7 (3 + 4), and cancer volume was 3.7cm
3 (IQR: 1.7-4.6). The technique was feasible in all cases. Perioperative complications included anastomotic leak (12%; G2), urinary tract infection (6%; G2), and transient intestinal ileus in one case (6%; G2). At 3 mo, continence and potency rates were 100% and 83%, respectively. Median nadir PSA was 0.4 ng/ml (IQR: 0.3-0.7). All margins and posterolateral margins rates were 55% and 35%, respectively. APC recurrence-free survival at 2 yr was 0.86 (95% confidence interval [CI], 0.55-0.96). Four patients (24%) who recurred underwent an uncomplicated completion of robot-assisted prostatectomy. Regarding limitations, CIs are quite wide for reported outcomes., Conclusions: Robotic partial prostatectomy for isolated APC is feasible with good functional results. While promising, much more research is needed to verify our initial outcomes and appropriately position APP in the treatment paradigms for APC., Patient Summary: We explored a novel approach for partial prostatic surgical ablation for prostate cancer located in the anterior part of the prostate as an alternative to other focal ablative techniques., (Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
40. Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
- Author
-
Villers A, Flamand V, Arquímedes RC, Puech P, Haber GP, Desai MM, Crouzet S, Ouzzane A, and Gill IS
- Subjects
- Humans, Male, Practice Guidelines as Topic, Prospective Studies, Prostatectomy methods, Prostatic Neoplasms surgery, Robotic Surgical Procedures
- Abstract
Objective: To describe a step-by-step guide to robot-assisted anterior partial prostatectomy (RA-APP) for isolated magnetic resonance imaging (MRI)-detected anterior prostate cancer (APC)., Patients and Methods: After Institutional Review Board approval, over an 8-year period (2008-2015), 17 consenting patients were enrolled in a prospective, single-arm, single-centre, Idea, Development, Evaluation, Assessment and Long-term evaluation of innovative surgery (IDEAL) phase 2a study. The inclusion criteria comprised pre-urethral, low-intermediate risk APC diagnosed by MRI and targeted biopsies. Patient position and port placement were identical to the transperitoneal RA radical prostatectomy procedure. Three steps of dissection were identified in the following order: (i) retrograde apical, after dorsal venous plexus division, transition zone (TZ) enucleation, and distal peripheral zone (PZ) sectioning; (ii) antegrade, at the bladder neck (BN) after anterior BN sectioning, TZ enucleation up to the verumontanum; and (iii) lateral dissections, including anterolateral PZ sectioning without incision of the endopelvic fascia. We report the incidence of perioperative complications. The RA completion of prostatectomy in four cases with cancer recurrence was performed at 0.3, 2.5, 2 and 2 years, respectively., Results: The RA-APP comprised en bloc excision of the anterior part of the prostate comprising of the anterior fibromuscular stroma, BN, prostate adenoma (TZ and median lobe) along with the proximal prostate urethra, PZ apical anterior horns, anterior aspect of the distal (sub-montanal) urethra, and anterior BN. The posterolateral parts of the PZ and distal (sub-montanal) urethra and peri-prostatic tissues were preserved intact. The bladder opening was sutured to the anterior sphincteric urethra wall and PZ lateral edges. The technique was feasible in all cases with no conversion to an open procedure. Perioperative complications were only Clavien-Dindo grade II. RA completion of prostatectomy was feasible in the four cases with cancer recurrence., Conclusion: PZ prostate-sparing RA-APP for isolated APC is feasible and safe, and represents an option for highly selected men with APCs as an alternative to other focal ablative therapy., (© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
41. Kidney tumors
- Author
-
Flamand V and Lamande N
- Abstract
Competing Interests: V. Flamand et N. Lamandé déclarent n’avoir aucun lien d’intérêts.
- Published
- 2017
42. Kidney cyst or cancer: diagnostic management
- Author
-
Flamand V and Lamande N
- Abstract
Competing Interests: Service d’urologie, hôpital Claude-Huriez, CHU de Lille, 59037 Lille Cedex, France
- Published
- 2017
43. Specific expression of heme oxygenase-1 by myeloid cells modulates renal ischemia-reperfusion injury.
- Author
-
Rossi M, Thierry A, Delbauve S, Preyat N, Soares MP, Roumeguère T, Leo O, Flamand V, Le Moine A, and Hougardy JM
- Subjects
- Animals, Cells, Cultured, Disease Models, Animal, Gene Knockout Techniques, Heme Oxygenase-1 metabolism, Hemin pharmacology, Kidney Diseases metabolism, Male, Membrane Proteins metabolism, Mice, Myeloid Cells cytology, Myeloid Cells drug effects, Oxidative Stress, Up-Regulation, Heme Oxygenase-1 genetics, Kidney Diseases etiology, Membrane Proteins genetics, Myeloid Cells metabolism, Reperfusion Injury metabolism
- Abstract
Renal ischemia-reperfusion injury (IRI) is a major risk factor for delayed graft function in renal transplantation. Compelling evidence exists that the stress-responsive enzyme, heme oxygenase-1 (HO-1) mediates protection against IRI. However, the role of myeloid HO-1 during IRI remains poorly characterized. Mice with myeloid-restricted deletion of HO-1 (HO-1
M-KO ), littermate (LT), and wild-type (WT) mice were subjected to renal IRI or sham procedures and sacrificed after 24 hours or 7 days. In comparison to LT, HO-1M-KO exhibited significant renal histological damage, pro-inflammatory responses and oxidative stress 24 hours after reperfusion. HO-1M-KO mice also displayed impaired tubular repair and increased renal fibrosis 7 days after IRI. In WT mice, HO-1 induction with hemin specifically upregulated HO-1 within the CD11b+ F4/80lo subset of the renal myeloid cells. Prior administration of hemin to renal IRI was associated with significant increase of the renal HO-1+ CD11b+ F4/80lo myeloid cells in comparison to control mice. In contrast, this hemin-mediated protection was abolished in HO-1M-KO mice. In conclusion, myeloid HO-1 appears as a critical protective pathway against renal IRI and could be an interesting therapeutic target in renal transplantation.- Published
- 2017
- Full Text
- View/download PDF
44. Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis.
- Author
-
Zheng F, Sparkes A, De Baetselier P, Schoonooghe S, Stijlemans B, Muyldermans S, Flamand V, Van Ginderachter JA, Devoogdt N, Raes G, and Beschin A
- Subjects
- Animals, CD11b Antigen metabolism, Cell Count, Choline, Concanavalin A, Disease Models, Animal, Hepatitis, Autoimmune pathology, Lectins, C-Type metabolism, Liver metabolism, Male, Methionine deficiency, Mice, Inbred C57BL, Prognosis, Tissue Distribution, Kupffer Cells metabolism, Liver pathology, Molecular Imaging methods, Single-Domain Antibodies chemistry
- Abstract
Purpose: Kupffer cells (KCs), the liver resident macrophages, are important mediators of tissue homeostasis and pathogen clearance. However, depending on the inflammatory stimuli, KCs have been involved in divergent hepato-protective or hepato-destructive immune responses. The versatility of KCs in response to environmental triggers, in combination with the specific biomarkers they express, make these macrophages attractive in vivo targets for non-invasive monitoring of liver inflammation or pathogenicity. This study aims to determine whether V-set and Ig domain-containing 4 (Vsig4) and C-type lectin domain family (Clec) 4, member F (Clec4F) can be used as imaging biomarkers for non-invasive monitoring of KCs during distinct liver inflammation models., Procedure: Flow cytometry (FACS), immuno-histochemistry (IHC), and single-photon emission computed tomography (SPECT) with Tc-99m labeled anti-Vsig4 or anti-Clec4F nanobodies (Nbs) was performed to evaluate in mice KC dynamics in concanavalin A (ConA)-induced hepatitis and in non-alcoholic steatohepatitis induced via methionine choline deficiency (MCD)., Results: In homeostatic mice, Nbs targeting Clec4F were found to accumulate and co-localize with Vsig4-targeting Nbs only in the liver. Upon induction of acute hepatitis using ConA, down-regulation of the in vivo Nb imaging signal was observed, reflecting reduction in KC numbers as confirmed by FACS and IHC. On the other hand, induction of steatohepatitis resulted in higher signals in the liver corresponding to higher density of KCs. The Nb-imaging signals returned to normal levels after resolution of the investigated liver diseases., Conclusions: Anti-Clec4F and anti-Vsig4 Nbs targeting KCs as molecular imaging biomarkers could allow non-invasive monitoring/staging of liver pathogenesis.
- Published
- 2017
- Full Text
- View/download PDF
45. Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.
- Author
-
Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, and Bensalah K
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell pathology, Disease-Free Survival, Female, Humans, Kidney Neoplasms pathology, Male, Margins of Excision, Middle Aged, Neoplasm, Residual, Retrospective Studies, Survival Rate, Young Adult, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Nephrons, Organ Sparing Treatments
- Abstract
Objective: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC)., Material and Methods: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed., Results: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively., Conclusion: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
- Author
-
Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, and Audenet F
- Subjects
- Benzamides, Docetaxel, Drug Resistance, Neoplasm, Drug Therapy, Combination, Humans, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin administration & dosage, Prostatic Neoplasms, Castration-Resistant pathology, Androstenes administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Phenylthiohydantoin analogs & derivatives, Prostatic Neoplasms, Castration-Resistant drug therapy, Taxoids administration & dosage
- Abstract
Purpose: To present a systematic review of the different therapeutic sequences in metastatic castration-resistant prostate cancer (mCRPC)., Methods: Evidence acquisition on therapeutic sequences in mCRPC was performed by a MEDLINE search using combination of the following key words: "prostate cancer," "metastatic," "castration resistant," "enzalutamide," "abiraterone," "treatment sequencing," "cabazitaxel," "docetaxel." A total of 17 studies were included for analysis., Results: Different sequences have been reported for the treatment of mCRPC: docetaxel after abiraterone, cabazitaxel after docetaxel and abiraterone, abiraterone after cabazitaxel and docetaxel, abiraterone after docetaxel and enzalutamide, and enzalutamide after docetaxel and abiraterone. There are arguments from the preclinical observations suggesting a cross-resistance between docetaxel and abiraterone, and between abiraterone and enzalutamide in mCRPC. Despite limitations, several retrospective clinical reports support these data., Conclusion: No study of high level of evidence is available to support any recommendation on sequential treatment for mCRPC. There are only clues that prospective clinical studies need to confirm.
- Published
- 2016
- Full Text
- View/download PDF
47. IL-12p40/IL-10 Producing preCD8α/Clec9A+ Dendritic Cells Are Induced in Neonates upon Listeria monocytogenes Infection.
- Author
-
Torres D, Köhler A, Delbauve S, Caminschi I, Lahoud MH, Shortman K, and Flamand V
- Subjects
- Animals, Antigen Presentation immunology, CD8 Antigens immunology, CD8-Positive T-Lymphocytes immunology, Dendritic Cells cytology, Dendritic Cells metabolism, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells immunology, Interleukin-10 biosynthesis, Interleukin-10 metabolism, Interleukin-12 Subunit p40 biosynthesis, Interleukin-12 Subunit p40 immunology, Lectins, C-Type immunology, Listeria monocytogenes immunology, Lymphocyte Activation immunology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Oligonucleotide Array Sequence Analysis, Receptors, Immunologic immunology, Transcriptome, Animals, Newborn immunology, Dendritic Cells immunology, Immunity, Innate immunology, Listeriosis immunology
- Abstract
Infection by Listeria monocytogenes (Lm) causes serious sepsis and meningitis leading to mortality in neonates. This work explored the ability of CD11c(high) lineage DCs to induce CD8+ T-cell immune protection against Lm in mice before 7 days of life, a period symbolized by the absence of murine IL-12p70-producing CD11c(high)CD8α+ dendritic cells (DCs). We characterized a dominant functional Batf3-dependent precursor of CD11c(high) DCs that is Clec9A+CD205+CD24+ but CD8α- at 3 days of life. After Lm-OVA infection, these pre-DCs that cross-present Ag display the unique ability to produce high levels of IL-12p40 (not IL-12p70 nor IL-23), which enhances OVA-specific CD8+ T cell response, and regulatory IL-10 that limits OVA-specific CD8+ T cell response. Targeting these neonatal pre-DCs for the first time with a single treatment of anti-Clec9A-OVA antibody in combination with a DC activating agent such as poly(I:C) increased the protection against later exposure to the Lm-OVA strain. Poly(I:C) was shown to induce IL-12p40 production, but not IL-10 by neonatal pre-DCs. In conclusion, we identified a new biologically active precursor of Clec9A+ CD8α- DCs, endowed with regulatory properties in early life that represents a valuable target to augment memory responses to vaccines.
- Published
- 2016
- Full Text
- View/download PDF
48. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.
- Author
-
Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, Baco E, Matsugasumi T, Chowaniec Y, Rigaud J, Lenormand C, Pfister C, Hetet JF, Ploussard G, Roupret M, Léon P, Bakri AE, Larré S, Tillou X, Doerfler A, Descazeaud A, Koutlidis N, Schneider A, Sebe P, Ingels A, Azzouzi AR, Soulié M, Méjean A, Bensalah K, and Patard JJ
- Subjects
- Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell surgery, Disease Progression, Disease-Free Survival, Female, France epidemiology, Humans, Kidney Neoplasms diagnosis, Kidney Neoplasms surgery, Male, Middle Aged, Nephrons surgery, Prognosis, Retrospective Studies, Risk Factors, Survival Rate trends, United States epidemiology, Carcinoma, Renal Cell classification, Kidney Neoplasms classification, Neoplasm Staging, Nephrectomy methods
- Abstract
Objectives: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death., Materials and Methods: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014., Results: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1-120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03)., Conclusion: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.
- Published
- 2016
- Full Text
- View/download PDF
49. Reply to Véronique Phé, Morgan Rouprêt, and Emmanuel Chartier-Kastler's Letter to the Editor re: Xavier Biardeau, Jérôme Rizk, François Marcelli, Vincent Flamand. Robot-assisted Laparoscopic Approach for Artificial Urinary Sphincter Implantation in 11 Women with Urinary Stress Incontinence: Surgical Technique and Initial Experience. Eur Urol 2015;67:937-42.
- Author
-
Biardeau X, Rizk J, Marcelli F, and Flamand V
- Subjects
- Female, Humans, Prosthesis Implantation instrumentation, Prosthesis Implantation methods, Robotics methods, Urinary Incontinence, Stress surgery, Urinary Sphincter, Artificial adverse effects
- Published
- 2016
- Full Text
- View/download PDF
50. Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.
- Author
-
Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, Flamand V, Heirman C, Thielemans K, and Breckpot K
- Subjects
- Animals, Biomarkers, CD27 Ligand genetics, CD40 Ligand genetics, Cell Line, Tumor, Cytotoxicity, Immunologic, Dendritic Cells metabolism, Disease Models, Animal, Female, Mice, Neoplasms mortality, Neoplasms pathology, Phenotype, RNA, Messenger administration & dosage, T-Cell Antigen Receptor Specificity, T-Lymphocytes metabolism, Toll-Like Receptor 4 genetics, Cross-Priming immunology, Dendritic Cells immunology, Lymphocyte Activation, Neoplasms genetics, Neoplasms immunology, RNA, Messenger genetics, T-Lymphocytes immunology
- Abstract
Modulating the activity of tumor-infiltrating dendritic cells (TiDC) provides opportunities for novel cancer interventions. In this article, we report on our study of the uptake of mRNA by CD8α(+) cross-presenting TiDCs upon its intratumoral (i.t.) delivery. We exploited this property to deliver mRNA encoding the costimulatory molecule CD70, the activation stimuli CD40 ligand, and constitutively active Toll-like receptor 4, referred to as TriMix mRNA. We show that TiDCs are reprogrammed to mature antigen-presenting cells that migrate to tumor-draining lymph nodes (TDLN). TriMix stimulated antitumor T-cell responses to spontaneously engulfed cancer antigens, including a neoepitope. We show in various mouse cancer models that i.t. delivery of TriMix mRNA results in systemic therapeutic antitumor immunity. Finally, we show that the induction of antitumor responses critically depends on TiDCs, whereas it only partially depends on TDLNs. As such, we provide a platform and a mechanistic rationale for the clinical testing of i.t. administration of TriMix mRNA., (©2015 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.